These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32085826)

  • 1. Research digest: next-generation lipoprotein therapeutics.
    Berberich AJ; Hegele RA
    Lancet Diabetes Endocrinol; 2020 Mar; 8(3):190. PubMed ID: 32085826
    [No Abstract]   [Full Text] [Related]  

  • 2. High HDL may not protect the heart. Concentrate on lowering LDL for now, experts advise.
    Harv Heart Lett; 2012 Sep; 23(1):6. PubMed ID: 23097807
    [No Abstract]   [Full Text] [Related]  

  • 3. Is raising HDL a futile strategy for atheroprotection?
    Joy T; Hegele RA
    Nat Rev Drug Discov; 2008 Feb; 7(2):143-55. PubMed ID: 18239670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges.
    Rosenson RS; Brewer HB; Ansell B; Barter P; Chapman MJ; Heinecke JW; Kontush A; Tall AR; Webb NR
    Circulation; 2013 Sep; 128(11):1256-67. PubMed ID: 24019446
    [No Abstract]   [Full Text] [Related]  

  • 5. The Zetia challenge: an update.
    Johns Hopkins Med Lett Health After 50; 2009 Apr; 21(2):6. PubMed ID: 19489149
    [No Abstract]   [Full Text] [Related]  

  • 6. Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease.
    Rosenson RS; Davidson MH; Hirsh BJ; Kathiresan S; Gaudet D
    J Am Coll Cardiol; 2014 Dec; 64(23):2525-40. PubMed ID: 25500239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
    Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
    J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular protective effects of ezetimibe: seeking new therapeutic possibilities of ezetimibe in vascular disease.
    Yamaoka-Tojo M
    Curr Vasc Pharmacol; 2011 Jan; 9(1):61. PubMed ID: 21044020
    [No Abstract]   [Full Text] [Related]  

  • 9. Lipid control in the modern era: an orphan's tale of rags to riches.
    Milani RV; Lavie CJ
    J Am Coll Cardiol; 2013 Dec; 62(23):2185-7. PubMed ID: 24013061
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment with statins: lowering of cholesterol or more?].
    Rutishauser J
    Praxis (Bern 1994); 2006 Jan; 95(4):107-10. PubMed ID: 16485605
    [No Abstract]   [Full Text] [Related]  

  • 11. HDL Cholesterol: Metabolic Pathways and Drug Developments. 4th International Conference, March 2-4, 2003, Cambridge, MA, USA.
    Scriabine A
    Cardiovasc Drug Rev; 2003; 21(2):143-50. PubMed ID: 12903649
    [No Abstract]   [Full Text] [Related]  

  • 12. Cholesterol-Lowering Agents.
    Rosenson RS; Hegele RA; Koenig W
    Circ Res; 2019 Feb; 124(3):364-385. PubMed ID: 30702994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease.
    Kei AA; Filippatos TD; Tsimihodimos V; Elisaf MS
    Metabolism; 2012 Jul; 61(7):906-21. PubMed ID: 22304839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atherosclerosis regression: is low-density lipoprotein or high-density lipoprotein the answer?
    Nicholls SJ; Tuzcu EM; Nissen SE
    Curr Atheroscler Rep; 2007 Oct; 9(4):266-73. PubMed ID: 18173953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do Oxidized Lipoproteins Cause Atherosclerotic Cardiovascular Diseases?
    Arsenault BJ; Bourgeois R; Mathieu P
    Can J Cardiol; 2017 Dec; 33(12):1513-1516. PubMed ID: 29100654
    [No Abstract]   [Full Text] [Related]  

  • 16. [Lower LDL and/or raise HDL. In what direction is lipidology moving?].
    Parhofer KG
    MMW Fortschr Med; 2007 May; 149(22):27. PubMed ID: 18069222
    [No Abstract]   [Full Text] [Related]  

  • 17. Torcetrapib as potential treatment of low high-density lipoprotein cholesterol: no longer a pipe dream?
    Ahmed MH
    Diabetes Technol Ther; 2008 Aug; 10(4):328-9. PubMed ID: 18715207
    [No Abstract]   [Full Text] [Related]  

  • 18. Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease.
    Nicholls SJ; Ray KK; Johansson JO; Gordon A; Sweeney M; Halliday C; Kulikowski E; Wong N; Kim SW; Schwartz GG
    Am J Cardiovasc Drugs; 2018 Apr; 18(2):109-115. PubMed ID: 29027131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From the editor: what are the important questions for clinical trials?
    Brown WV
    J Clin Lipidol; 2012; 6(4):299-300. PubMed ID: 22836064
    [No Abstract]   [Full Text] [Related]  

  • 20. [Statin therapy].
    Hitzenberger G
    Wien Med Wochenschr; 2003; 153(11-12):242-3. PubMed ID: 12879631
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.